Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

References

• Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003;22: 331–9
   Google Scholar
• Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am 2003;32:805–22
   PubMed Web of Science ®Google Scholar
• Stein CJ, Colditz GA. The epidemic of obesity. J Clin Endocrinol Metab 2004;89:2522–5
   PubMed Web of Science ®Google Scholar
• Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the U.S.: 1990–1998. Diabetes Care 2000;23: 1278–83
   Google Scholar
• Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76–9
   PubMed Web of Science ®Google Scholar
• Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004;89:2583–9
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H, Westerbacka J. The fatty liver and insulin resistance. Curr Molec Med 2005;5:287–95
   PubMed Web of Science ®Google Scholar
• Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus. Diabetes Care 2007;30:162–72
   PubMed Web of Science ®Google Scholar
• Williamson DF, Thompson TJ, Thun M, et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000;23:1499–1504
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837–53
   Google Scholar
• UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 28. A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998;21: 87–92
   Google Scholar
• Koro CM, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diganosed with type 2 diabetes. Diabetes Care 2004;27:17–20
   PubMed Web of Science ®Google Scholar
• Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002;137:25–33
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:541–9
   PubMed Web of Science ®Google Scholar
• American Gastroenterological Association. Medical position statement: nonalcoholic fatty liver disease. Gastroenterology 2002;123:1702–4
   PubMedGoogle Scholar
• American Gastroenterological Association. Technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705–25
   PubMedGoogle Scholar
• Raz I, Eldor R, Cernea S, et al. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metab Res Rev 2005;21:3–14
   PubMed Web of Science ®Google Scholar
• Webb DM, Wintle M, Malone JK. Exenatide effects on glucose metabolism and metabolic disorders common to overweight and obese patients with type 2 diabetes. Drug Devel Res 2006;67: 666–76
   Google Scholar
• Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a noninferiority study. Diabetologia 2007;50:259–67
   PubMed Web of Science ®Google Scholar
• Zinman B, Hoogwerf BJ, Garcia SD, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med 2007;146:477–85
   PubMed Web of Science ®Google Scholar
• Mack CM, Laugero KD, Liu Q, et al. Therapeutic applications of incretin mimetics for metabolic diseases: preclinical studies. Drug Dev Res 2006;67:553–8
   Web of Science ®Google Scholar
• Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628–35
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092–1100
   PubMed Web of Science ®Google Scholar
• Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083–91
   PubMed Web of Science ®Google Scholar
• Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007;29:139–53
   PubMed Web of Science ®Google Scholar
• Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8:436–47
   PubMed Web of Science ®Google Scholar
• Declaration of Helsinski: Recommendations guiding medical physicians in biomedical research involving human subjects. JAMA 1997;277:925–6
   PubMed Web of Science ®Google Scholar
• Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1–10
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001;24:758–67
   PubMed Web of Science ®Google Scholar
• Purnell JQ, Weyer C. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol 2003;2:33–47
   PubMedGoogle Scholar
• Makimattila S, Nikkila K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia 1999;42:406–12
   Google Scholar
• Angulo P. Current best treatment for non-alcoholic fatty liver disease. Exp Opinion Pharmacother 2003;4:611–23
   PubMed Web of Science ®Google Scholar
• Ding X, Saxena NK, Lin S, et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006;43:173–81
   PubMed Web of Science ®Google Scholar
• Tushuizen ME, Bunck MC, Pouwels PJ, et al. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006;26:1015–17
   PubMed Web of Science ®Google Scholar